An additional aspect of our work is the development of cancer drug screens for cell cycle and apoptosis pathway targets.

An additional aspect of our work is the development of cancer drug screens for cell cycle and apoptosis pathway targets. This includes the identification and validation of new targets developed within the lab or in collaboration with other Breakthrough Research Centre and ICR labs. Currently, we are involved in screening for inhibitors for a variety of targets with oncogenic activity.